The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

Society of Toxicology 2010 Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). Mouse Liver...................................... 244 mouse lymphoma............................ 1697 mouse lymphoma assay............ 694, 695 mouse model..................................... 741 mouse models....................... 1333, 1334 mouse stem cell.............................. 1680 Mouse strains.................... 299, 362, 589 MPP+.............................................. 1270 MPTP.................................... 1225, 1390 MRL............................................... 1029 mRNA............................................. 2040 mRNA expression............................. 589 mRNA stability................................. 760 Mrp2............................................... 1623 Mrp3............................................... 1597 MRP4.............................................. 1469 MTF-1 activation mechanism......... 1812 MTT Assay....................................... 183 mucin.............................................. 1764 Mucosal Immunoregulation.............. 538 mucosal inflammation.................... 2021 Multi-drug resistance transporter... 1749 Multi-walled carbon nanotube......... 794, 795, 1397, 1399 Multidrug Resistance Proteins.......... 626 multidrug resistance transporters.... 1417 multielectrode array........................ 1738 multiparametric analysis................... 199 multiple sclerosis............................ 1282 Multiplex........................................ 1995 multipurpose solution..................... 1168 multiroute exposure........................ 1579 multiwalled carbon nanotube........... 805 munitions........................................ 2185 murine HIPEC................................ 2009 murine local lymph node assay....... 300, 1807 muscarinic receptor.......................... 288 mustard............................................. 347 mutagen.......................................... 1922 Mutagenesis.............................. 121, 689 mutagenic activity............................. 701 Mutagenicity................................... 1144 mutation.................................... 690, 691 mutation analysis............................ 1862 mutational analysis......................... 1863 mutiwall carbon nanotube.............. 1396 Myc................................................. 1758 Mycophenolic Acid.......................... 405 mycotoxin..................... 853, 1167, 1456 Myeloperoxidase.............................. 716 myopathy.............................. 1315, 1673 Myotoxicity.................................... 1325 n-3 polyunsaturated fatty acids....... 1784 N-Acetyl-L-Cysteine........................ 183 N-acetylglycine............................... 1155 n-alkane............................................ 875 n-butyl glycidyl ether...................... 1587 N-methyl-d-aspartate........................ 179 N-nitroso compounds....................... 778 N6AMT1.......................................... 951 NADPH oxidase..... 233, 762, 909, 1557 NADPH-cytochrome p450 reductase................................. 765, 2128 NAFLD..................................... 555, 556 NAG-1.............................................. 400 nano........................................ 367, 1281 Nano particle.................................... 792 Nano-Cu......................................... 2071 Nano-materials............................... 1395 Nano-Nickel..................................... 368 nano-sized particles............................ 22 nanomaterial............................. 263, 794 Nanomaterials.......... 255, 265, 280, 284, 290, 372, 801, 1693, 2039, 2040, 2181, 2212 nanoparticle.... 261, 273, 275, 282, 1478 nanoparticles............ 234, 257, 258, 259, 262, 266, 270, 271, 272, 274, 276, 278, 286, 288, 289, 291, 370, 372, 528, 608, 793, 849, 1398, 1695, 1696, 1705, 1707, 1728, 2035, 2072, 2073 Nanoparticles or Ultrafine Particles.......................................... 2183 nanosilica.......................................... 268 nanosilver....................................... 1697 nanotechnology................................. 790 nanotherapeutics................... 1479, 1480 Nanotoxicity..................................... 281 Nanotoxicology....... 255, 256, 264, 269, 279, 285, 372, 791, 835, 1403, 1693, 1694, 1698, 1703, 1706, 1707, 2042, 2044 nanotubes................................ 790, 2041 nanozinc.......................................... 2066 naphthalene....... 1329, 1494, 1861, 1881 nasal mucosa................................... 1099 nasal passages................................... 868 nasal respiratory epithelium........... 1596 nasal trigeminal neuron.................. 2019 NASH............................................... 148 National Children’s Study............... 651, 652, 655 Natural Product................................. 687 Natural Products......... 1132, 1179, 1783 NBT Staining...................................... 54 necrosis......................... 594, 1165, 1223 Nei-like DNA glycosylase................ 702 NEMO............................................ 1065 Neonatal exposure.......................... 1298 neonatal mice.................................... 388 neonates............................................ 385 neopterin......................................... 1046 nephron............................................... 12 nephropathy...................................... 813 Nephrotoxicant................................. 824 Nephrotoxicity......... 808, 815, 818, 819, 822, 1140, 1314, 1330, 1409, 1924 nephrotoxicity biomarkers..... 807, 1322, 1323 nephrotoxicology.............................. 577 Neprilysin....................................... 1512 nerve agent........................................ 333 Nerve agents............................. 321, 354 networking........................................ 660 networks......................................... 2011 neural development........................... 936 neural differentiation...................... 2070 Neural Tube Defect........................... 860 neurite outgrowth............................ 1389 Neuritic degeneration..................... 1613 neurobehavior................................. 1264 neurobehavioral changes.................... 23 neurobehavioral toxicology..... 166, 893, 1390, 2023, 2026 neurobehaviour..................... 1025, 1068 Neurodegeneration......... 184, 587, 1277, 1285, 1290, 1292 neurodegenerative disease...... 977, 1615 neurodevelopment.................. 482, 1394 neurodevelopmental toxicity............ 859 neuroendocrine................................. 406 neurofilament.................................. 1267 Neurogenesis.................................. 1609 neuroinflammation.......... 24, 345, 1272, 1285, 1970 neurological.................................... 1185 neuropathology................................. 161 neuropathy...................................... 1281 Neuropathy Target Esterase.............. 833 Neuropathy target esterase (NTE).. 1381 neuroprogenitor cell.......................... 156 Neuroprotection.................... 1273, 1276 Neurotoxicity............... 19, 21, 158, 217, 223, 467, 796, 798, 845, 985, 987, 991, 993, 995, 997, 999, 1235, 1238, 1244, 1258, 1263, 1264, 1272, 1289, 1605, 1608, 1611, 1932, 2025, 2038 neurotoxicology........... 174, 1059, 1189, 1276, 1602, 2034 neurotoxin....................................... 1284 neurotoxins....................................... 988 neutrophil................................ 766, 1519 Nevirapine...................... 316, 449, 1951 new method..................................... 1124 new paradigms.................................. 647 new technologies............................ 1353 New Zealand White Rabbits............. 852 Next generation sequencing............ 1662 NF kappa B....................................... 959 NF-kappa B.................................... 1260 NF-kB............................................. 1065 NF-kB................................... 1539, 1544 NHANES.............. 640, 666, 1847, 1869 nickel................... 441, 525, 1800, 1819, 1944, 2159, 2160, 2162 nicotinamide nucleotide transhydrogenase.................................767 nicotine........................... 176, 447, 1599 Nimodipine..................................... 1257 Nitric Oxide.................. 969, 1744, 1823 Nitrile.............................................. 1253 Nitrogen dioxide............................... 480 nitrogen mustard................................. 67 nitrosamines.................................... 1588 nitroso compounds.......................... 1652 NK cell...................................... 35, 1547 NK cells................................ 1984, 1987 NLRP3 inflammasome....................... 33 NMDA............................................ 1324 NMR....................................... 809, 1256 NNK........................................... 93, 129 NO2.................................................. 670 NO 2 ................................................. 1886 NOAEL........................................... 1003 noise................................................ 1265 Non Human Primate......................... 921 non human primates......................... 842 Non-alcoholic fatty liver disease... 1625, 1626 non-animal testing........ 114, 2215, 2217 non-cellular....................................... 261 nonclinical...................................... 1375 non-dioxinlike................................. 2061 non-extractable radioactivity............ 458 Non-Human Primate................. 600, 935 non-human primates............... 937, 1981 Non-Invasive................................... 1727 non-invasive monitoring................... 915 Non-invasiveness...................... 604, 940 Non-pregnant and lactating rats...... 1569 Non-rodent toxicology studies....... 1805 non-steroidal anti-inflammatory......... 94 noncancer............................................ 40 nonclinical safety assessment......... 1802 nongenotoxic.................................. 2156 non-human primate........................... 832 Nonylphenol........................... 411, 2148 Normal Neural Development............ 862 NOS2.............................................. 1296 NovaSil clay......................... 1160, 1161 novel gene......................................... 704 NQO1............................................... 724 nrf-2.................................................. 772 Nrf2................................................... 775 NSAIDs.................................. 294, 2144 NSAIDs with Steroids...................... 924 NTP-200 feed................................. 1588 Nuclear factor E2-related factors...... 962 Nuclear Factor Erythroid 2............... 747 nuclear hormone receptors............. 1069 nuclear receptor............. 139, 622, 1210, 1407, 1472, 2085, 2147, 2154, 2155 Nuclear Receptors..... 5, 229, 575, 1346, 2145 nucleoside reverse transcriptase inhibitor.......................................... 1743 Nucleotide Reverse Transcriptase Inhibitor.......................................... 1057 numerical chromosome aberrations.. 123 o-anisidine........................................ 141 o-toluidine....................................... 1912 obesity................ 59, 554, 558, 585, 668, 752, 1143, 1327, 1507, 1621, 1623, 1624, 1785, 1972 observation........................................ 916 occupational.................................... 1793 occupational asthma......................... 304 Occupational Exposure......... 1396, 1831 occupational exposures......... 1242, 1792 occupational nickel exposure.......... 2158 occupational safety......................... 1169 OCT.................................................. 921 oct-4.................................................. 964 ocular.................... 99, 1056, 1168, 2213 ocular safety testing.......................... 100 Ocular tissue............................. 487, 719 ocular toxicity............................... 8, 932 Ocular toxicology............................. 479 OECD Guidance Notes................... 2051 OECD Toolbox................................. 205 OGG1............................................... 936 olfactory.............................................. 20 olfactory epithelium........................ 1596 Olfactory sensory neurons.............. 1216 oligonucleotide............................... 2082 omega 3 fatty acids..... 1146, 1147, 1148 Omic biomarkers................................ 53 ‘omics............................................. 1654 oncology............................... 1050, 1787 oncology drugs............................... 1273 Oncomodulin.................................. 1300 Ontogeny........................................ 1621 OP antagonism.................................. 349 OP6 olfactory sensory neuron cell line........................................... 1215 operant behavior............................... 180 OPH formulation.............................. 349 OPIDN.................................. 1233, 1257 optic tectum...................................... 165 Optimal Sampling Strategy............ 1846 oral polymer.................................... 1803 Organ Weight.................................. 1027 organ-specific toxicity...................... 699 organic cation transporters.............. 1584 organophosphate...... 168, 242, 324, 335, 346, 1028, 1255, 1256, 1897 organophosphate induced delayed neuropathy...................................... 1266 organophosphate pesticide............. 1230, 1248, 1264 organophosphate pesticides............ 1242 Organophosphate Toxicity................ 345 organophosphates...... 1252, 1391, 1866, 1893 organophosphorus........................... 1249 organophosphorus insecticides........ 897, 1716, 1896 Organophosphorus pesticides........ 1238, 1240, 1263 organotypic cell culture....... 1661, 1966, 1967 organotypic model............................ 412 oseltamivir...................................... 1052 osmotic stress.................................... 595 osteoblast........................................ 1820 osteopontin........................... 1553, 1784 osteoporosis.................................... 1827 ovalbumin....................................... 2020 ovarian cancer....................... 2003, 2009 Ovarian follicle......................... 377, 383 Ovarian follicle growth..................... 398 Ovarian function............................... 919 Key Word Index SOT 2010 Annual Meeting 503
49 th Annual Meeting and ToxExpo Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). Key Word Index Ovarian toxicity........ 25, 27, 28, 29, 377 ovariectomy...................................... 930 Ovary............. 25, 26, 29, 384, 387, 388, 395, 402, 1485, 1489 ovotoxicity........................................ 402 Oxamyl........................................... 1034 Oxidant Stress................................... 594 oxidative......................................... 1697 Oxidative Damage.................... 142, 708 oxidative DNA damage.................... 238 oxidative injury..... 277, 998, 1277, 2177 oxidative lipidomics......... 597, 598, 599 oxidative phosphorylation................ 186 Oxidative potential........................... 254 Oxidative stress...... 59, 65, 80, 149, 222, 268, 311, 352, 369, 373, 382, 385, 517, 526, 529, 578, 595, 710, 751, 752, 761, 765, 768, 772, 774, 777, 779, 782, 783, 785, 796, 798, 804, 818, 823, 990, 992, 994, 1220, 1226, 1263, 1268, 1327, 1469, 1474, 1590, 1635, 1749, 1893, 1955, 1956, 1957, 2036, 2038, 2065, 2093 Oxidative stress signaling................. 592 Oxidative stress, DNA damage, Toxicity............................................. 510 Oxidative stress, functional genomics......................................... 1699 Oxidative stress; DNA adducts....... 1704 oxime................................................ 899 oximes............................................... 325 oxLDL.................................. 1511, 1954 oxychlordane.................................... 220 Oxyfluorfen.................................... 1903 Oysters.............................................. 434 ozone............................. 738, 1500, 2139 P-glycoprotein................ 358, 984, 1210 p27.................................................... 518 p27kip1............................................. 413 p38 Kinase inhibitor....................... 1114 p38 MAP kinase................................. 61 p38 MAP kinase inhibitor................ 903 p38 mitogen activated protein kinase.............................................. 1699 P450........ 1087, 1095, 1096, 1099, 1139 P450 CYP3A.................................. 1093 P450s.............................................. 1892 p53........................... 133, 496, 591, 710, 715, 727, 1781 PAH................ 128, 355, 453, 736, 1521 PAHs....................................... 685, 1038 PAI-1............................................... 2071 PAL................................................. 1028 palaemonetes pugio.......................... 424 Pancreas...................... 1075, 1076, 1077 PAR2................................................. 484 parallel deletion analysis.......... 115, 224 Parallelogram Method.................... 2161 Parameter Uncertainty...................... 873 paraoxon................................... 176, 334 Paraoxonase 1................................... 239 Paraquat....... 630, 764, 769, 1231, 1261, 1898 Parkinson Disease........................... 1292 Parkinson’s....................................... 272 Parkinson’s Disease....... 358, 986, 1231, 1236, 1261, 1268, 1271, 1274, 1275, 1278, 1280, 1286, 1287, 1290, 1291, 1293, 1294 Parkinsonism...................................... 21 Parkinsons Disease......................... 1270 PARP-1............................................. 706 particle.............................................. 441 particles................................. 1401, 1475 Particulate....................................... 2151 Particulate Matter.......... 760, 934, 1496, 1498, 1501, 1502, 1508, 1518, 1522, 1856, 2176 Particulate Matter (PM2.5)..... 730, 1560 particulate matter air pollution....... 1507 particulates.......................................... 92 Partition Coefficient................ 876, 1567 Partition coefficients......................... 880 Partitioning....................................... 639 Parvalbumin...................................... 178 PAS................................................... 982 PAS Kinase..................................... 1357 Passive sampling device................. 1008 patch clamp..................................... 2031 patch clamping................................ 1739 pathogenesis..................................... 327 Pathology.................................. 26, 1319 pathway............................................. 212 pathway enrichment........................ 1645 pathways......................................... 1447 patulin............................................. 1461 PBDE.............................................. 2063 PBDE metabolites.................... 217, 223 PBDEs...... 155, 222, 241, 642, 643, 644 PBP................................................. 1359 PBPK............... 565, 874, 878, 881, 896, 901, 1567, 1894 PBPK model........... 568, 875, 888, 1384 PBPK Modeling....... 879, 880, 883, 885, 886, 892, 893, 899, 1041, 1564 PBPK parameters.............................. 882 PBPK/PD Model............................ 1900 PBPK/PD Modeling......................... 325 PC12 cells......................................... 991 PCB..................... 892, 1280, 1748, 2189 PCB126..................................... 239, 240 PCB153............................................. 234 PCB3 metabolits............................... 716 PCBs....... 155, 157, 173, 175, 233, 236, 2064 PCR Arrays..................................... 1660 PDE inhibitor.................................. 1725 PDTC.............................................. 1898 Pectin gelation................................ 1460 peer review...................................... 1797 peptide reactivity...................... 110, 308 peptides............................................. 494 perchlorate............................ 2094, 2099 perchloroethylene........................... 1946 perfluorinated chemicals.......... 225, 580 perfluorinated compounds.............. 1555 perfluoroalkyl acid.......................... 2112 Perfluoroalkyl acids........ 428, 830, 1590 Perfluoroalkyl compounds.............. 1188 Perfluorohexanesulfonate............... 1585 perfluorooctanesulfonate................ 1590 Perfluorooctanoate.................. 820, 1586 perfluorooctanoic acid...................... 218 Performance reference compound....1008 perinatal exposure........................... 1591 period.............................................. 1829 Peripheral Neuropathy.................... 1273 peripubertal testis.............................. 410 Permeability...................................... 503 permeation...................................... 1101 peroxidase....................................... 1151 peroxisome proliferator-activated receptor gamma.......... 1549, 1551, 2004 Peroxisome proliferator-activated receptor- b/d................................... 2142 peroxisome proliferators................. 2207 Peroxynitrite........................... 709, 2129 Personal Care Products............. 106, 485 Pesticide...1034, 1037, 1867, 1902, 2190 Pesticide Exposure.......................... 2049 Pesticide kinetics............................ 1569 Pesticide Mixtures.......................... 1235 Pesticides............. 182, 654, 1467, 1567, 1890, 1891, 1895, 1905, 2027, 2050 petroleum substance............. 1122, 1799 PFAAs............................................. 1384 PFCA................................................ 226 PFHxS............................................. 1585 PFNA................................................ 219 PFOA....................... 221, 229, 407, 839, 1578, 1586, 2194 PFOA/PFOS..................................... 580 PFOS............................. 229, 1554, 1578 PHAHs.............................................. 238 pharmaceutical........................ 646, 1708 Pharmaceutical agents...................... 318 Pharmaceuticals....... 232, 432, 437, 459, 1184 Pharmacodynamics............... 1047, 1757 pharmacogenetics........................... 1335 Pharmacogenomics....... 365, 1661, 1966 pharmacokinetic.................... 218, 1581, 1591, 1592 pharmacokinetic and pharmacodynamic modeling............................... 1047, 1757 pharmacokinetic model.................. 1580 Pharmacokinetic models................... 887 pharmacokinetics............... 20, 280, 543, 544, 884, 1047, 1158, 1576, 1583, 1585, 1593, 1594, 1757, 1887, 2069 Pharyngeal Aspiration.................... 1859 Phase II enzymes............................ 1234 phase-I enzymes............................... 589 Phencyclidine (PCP)......................... 169 Phencynonate.................................... 321 phenobarbital................ 533, 1950, 1967 Phortress................................. 481, 1406 phosphatase............................. 723, 1671 phosphate transporter........................ 949 phosphatidylserine.......................... 1217 Phosphodiesterase Inhibitors (PDE).1744 phospholipase................................... 519 phospholipidosis...... 200, 204, 208, 720, 1318, 1656, 1658 phosphoramidates........................... 1249 phosphorylation................................ 129 photo-allergenicity.............................. 91 Photogenotoxicity........................... 1107 photomutagenicity............................ 693 phototoxicity............... 91, 189, 263, 922 phthalate...................... 190, 1481, 1487, 1489, 2089, 2155 Phthalate (2-ethylhexyl) ester......... 1541 phthalate ester................................. 1486 Phthalates......... 559, 560, 561, 562, 563, 564, 566, 1149, 1470, 1485, 1488, 1907, 1908 phthalimide..................................... 1326 Physical exertion............................... 887 Physiological Parameters................ 1564 Physiologically Based Pharmacokinetic models............................................... 889 Physiologically-based Pharmacokinetic Model................................................ 877 phytoestrogens.................................. 390 phytostanols.................................... 1809 phytosterols..................................... 1809 Phytotoxicity..................................... 255 PI3K................................................ 1060 Picramic acid.................................. 1009 Pig Model......................................... 924 Pig-A......................................... 690, 691 PINK1............................................. 1278 piperine........................................... 1767 PKC and CK2................................. 1812 PKD1.............................................. 1268 PKG................................................ 1734 PLA 2 ................................................. 593 placenta............................................. 378 plant biotechnology........................ 1181 Plant Protection Products............... 2051 plasticizer.......................................... 418 Platelets........................................... 1166 Platinum.......................................... 1925 Platycodon grandiflorum..... 1764, 1765, 1775, 1776 Play areas.......................................... 968 pleural plaque................................. 1875 Pleurotus eryngil............................. 1772 pluripotent cells.................................. 49 PM10.............................. 254, 759, 1519 PM2.5..................................... 287, 1474 poisoning........................................ 1902 Policy.............................................. 1798 pollutants........................................ 1883 pollution burden.............................. 1906 poly (ADP-ribose) polymerase (PARP)............................................ 1953 polyalkylene glycols....................... 1499 Polybrominated diphenylether.......... 426 Polychlorinated Biphenyl............... 2103 polychlorinated biphenyls....... 177, 893, 2061, 2062 polychlorinated biphenyls (PCBs )........................... 162, 454, 1033 polycyclic aromatic hydrocarbon... 1668 polycyclic aromatic hydrocarbon (PAH).............................................. 1122 polycyclic aromatic hydrocarbons............................ 171, 180 Polycyclic Aromatic Hydrocarbons (PAH)........................................ 684, 698 Polyfluroalkyl chemicals.................. 640 polyhalogenated aromatic hydrocarbons.................................. 1173 Polymorphism........................... 356, 360 polymorphisms................................. 361 polyol pathway............................... 1959 PON1................................................ 360 Poorly soluble particles.................. 1794 POP mixtures.................................... 244 POPs......................................... 638, 639 POPs in Food.................................... 641 population exposures........................ 570 Populations..................................... 1448 Porcine Ocular Reversibility Assay....485 portable x-ray fluorescence (XRF)................................................1884 Positive reinforcement...................... 920 postdoctoral...................................... 662 postmenopausal women.................... 930 Potassium current............................. 729 PPAR........................... 825, 1325, 1359, 2141, 2143, 2207 PPAR alpha..................................... 1630 PPAR gamma agonist....................... 516 PPAR-alpha.................................... 1554 PPAR-gamma, PEPCK..................... 725 PPARalpha-null................................ 219 PPARs............................................... 469 PPARb/d......................................... 2144 PPARg....................................... 60, 1300 PPO................................................. 1948 PPO inhibitor.................................. 1948 precision cut lung slices.......... 481, 1406 preclinical....................................... 1081 Preclinical Safety............................ 1810 Preclinical Safety evaluation.............. 11 Preclinical Toxicology............ 918, 1577 Prediction Model.............................. 202 predictive ecotoxicology................. 1450 Predictive testing................................ 13 Predictive Toxicology........... 1078, 1640 Pregnancy success-rate..................... 392 pregnane X receptor.... 1133, 2077, 2102 Pregnant.......................................... 1385 Pregnant rat and fetus..................... 1383 prenatal........................................... 1750 prenatal cigarette smoke................. 1974 prenatal stress................................. 1614 Prenylation...................................... 1674 pressure sensors.............................. 2022 Preterm Birth.................................... 422 prevalence rate................................ 1875 Primaquine........................................ 905 Primary B Cell................................ 1533 Primary dendritic cells...................... 107 primary hepatocyte......................... 1717 primary hepatocytes.......................... 118 504 SOT 2010 Annual Meeting
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIOLOGICAL PATHWAY ANALYSIS: AN I
Page 7 and 8:
11 ICH INITIATIVES FOR CONDUCTING P
Page 9 and 10:
models. Experimental approaches and
Page 11 and 12:
30 SILICA AND ASBESTOS IMMUNOTOXICI
Page 13 and 14:
40 NONCANCER TOXICITY POTENTIAL AT
Page 15 and 16:
ased products for patient administr
Page 17 and 18:
nase regulates Hsp27-induced reorga
Page 19 and 20:
exposure resulted in splenomegaly.
Page 21 and 22:
We investigated the effect of imati
Page 23 and 24:
well plate prevented free cell move
Page 25 and 26:
98 DERIVING SIGNATURES OF IN VIVO T
Page 27 and 28:
sulfate, cinnamic aldehyde, 2,4-din
Page 29 and 30:
The final product will be a system
Page 31 and 32:
mercially available STP brands by m
Page 33 and 34:
for six weeks, with 10 mg/kg azoxym
Page 35 and 36:
eceived RES post-TCDD exposure when
Page 37 and 38:
morigenesis. Knocking down of JARID
Page 39 and 40:
163 MICROPET IMAGING OF [18F]-DFNSH
Page 41 and 42:
These results are comparable to tha
Page 43 and 44:
activity as assessed by lever press
Page 45 and 46:
for measured physico-chemical param
Page 47 and 48:
199 DEVELOPMENT OF A MULTIPARAMETER
Page 49 and 50:
To cause PLD, a drug needs to enter
Page 51 and 52:
In contrast to the parent PBDEs and
Page 53 and 54:
transiently transfected HEK 293 cel
Page 55 and 56:
TCDD exposure, 24 h prior to a 20 %
Page 57 and 58:
244 NON-ADDITIVE EFFECTS OF PCB153
Page 59 and 60:
253 COMPARISON OF MIXTURE TOXICITY
Page 61 and 62:
two cerium oxide nanoparticles of v
Page 63 and 64:
271 SIZE-DEPENDENT EFFECTS OF TUNGS
Page 65 and 66:
adigms such as Tox 21 and Toxcast,
Page 67 and 68:
QDs with emission maximum at 800nm
Page 69 and 70:
Cleveland, while others were found
Page 71 and 72:
without the need of animal testing.
Page 73 and 74:
Conclusions: These results are cons
Page 75 and 76:
ing oxime reactivation and organoph
Page 77 and 78:
335 A NON-OXIME IMPROVES SURVIVAL I
Page 79 and 80:
alties suffer from permanent lung i
Page 81 and 82:
ies have established inflammatory b
Page 83 and 84:
363 GENETIC VARIATION IN ISOGENIC M
Page 85 and 86:
372 EVALUATING THE BIOLOGICAL INTER
Page 87 and 88:
dose of 1/20 LD50 (400 mg/kg.bwt) f
Page 89 and 90:
median CR-adjusted isoflavone conce
Page 91 and 92:
data indicate that AhR deletion pro
Page 93 and 94:
February 2006). The rabbit is one o
Page 95 and 96:
tal neurotoxicity (DNT) test (OECD
Page 97 and 98:
of selected microorganisms that are
Page 99 and 100:
BVI. Histopathological analysis was
Page 101 and 102:
446 MOLECULAR CLONING AND CHARACTER
Page 103 and 104:
portant in predicting risk. CYPs 1A
Page 105 and 106:
ats, which involves metabolic activ
Page 107 and 108:
473 BOVINE CORNEAL OPACITY AND PERM
Page 109 and 110:
482 TYPE III DEIODINASE (D3) IS PRO
Page 111 and 112:
tancy evaluation and ranking of bat
Page 113 and 114:
501 CHARACTERIZATION OF ESTERASE, G
Page 115 and 116:
510 REDOX CYCLING BY ENDOGENOUS 2-
Page 117 and 118:
prostate cancer cells. All 8 BEL de
Page 119 and 120:
metallic nickel nanoparticles. Acti
Page 121 and 122:
variety of more or less reactive ch
Page 123 and 124:
550 QUALIFICATION STRATEGIES-GENOTO
Page 125 and 126:
ferentiation, and 3) how mixtures o
Page 127 and 128:
572 LOW-CHRONIC ARSENIC EXPOSURE: E
Page 129 and 130:
582 IDENTIFICATION OF SENSITIVE URI
Page 131 and 132:
duced by the genetic outcross of fe
Page 133 and 134:
fects of new compounds are equally
Page 135 and 136:
acterize the current state of the s
Page 137 and 138:
620 CHARACTERIZATION OF POTENTIAL I
Page 139 and 140:
ways. Moreover, both MAP kinase and
Page 141 and 142:
641 POPS IN THE U.S. POPULATION AND
Page 143 and 144:
studies such as the NCS, consider h
Page 145 and 146:
the beginning of the academic caree
Page 147 and 148:
trophil infiltration, a significant
Page 149 and 150:
tactic response and optokinetic res
Page 151 and 152:
usually high spontaneous PIG-A MFs.
Page 153 and 154:
699 PROMUTAGEN ACTIVATION AND P450
Page 155 and 156:
oxodG in bone marrow, spleen, kidne
Page 157 and 158:
718 GENOTOXICITY OF ORGANIC EXTRACT
Page 159 and 160:
ment were 18.0 and 4.5 nM for BEAS-
Page 161 and 162:
strongest activation of nuclear fac
Page 163 and 164:
746 MACROPHAGE INHIBITORY CYTOKINE-
Page 165 and 166:
screening of cell migration. High-c
Page 167 and 168:
dase inhibition). In contrast, inhi
Page 169 and 170:
mice; the decrease was more pronoun
Page 171 and 172:
Markers of oxidative damage reached
Page 173 and 174:
793 PULMONARY RESPONSE, OXIDATIVE S
Page 175 and 176:
cilitate clinical and industrial ap
Page 177 and 178:
sion of p-p38, p-p53, p21 and cycli
Page 179 and 180:
821 KIDNEY INJURY MOLECULE-2 GENE D
Page 181 and 182:
commercial applications, and have b
Page 183 and 184:
developmental effects. The residual
Page 185 and 186:
strand breaks in an in vitro model
Page 187 and 188:
etate (immunotoxicity). 2,4-D was t
Page 189 and 190:
867 MELATONIN AMELIORATES CYCLOPHOS
Page 191 and 192:
pharmacokinetic (PBPK) models. Ten
Page 193 and 194:
of radiolabeled Mn (carrier-free 54
Page 195 and 196:
893 UNVEILING ASSOCIATIONS BETWEEN
Page 197 and 198:
using area under the concentration
Page 199 and 200:
912 COMMERCIAL FISH DIETS INDUCE VI
Page 201 and 202:
922 A STUDY OF PHOTOTOXICITY FOLLOW
Page 203 and 204:
from 0.1 to 2.9 g/L (saturated vapo
Page 205 and 206:
vasive method for assessing several
Page 207 and 208:
950 ARSENITE DOWN-REGULATES THE CAR
Page 209 and 210:
inflammatory signaling is altered b
Page 211 and 212:
treated wood. Seventy-five of 132 w
Page 213 and 214:
ergy homeostasis and raising levels
Page 215 and 216:
treated with mercury and then with
Page 217 and 218:
997 IN VIVO CORRELATES OF THE MANGA
Page 219 and 220:
of the panel. The panel was compris
Page 221 and 222:
sponse, location, and severity scor
Page 223 and 224:
tant source of n-3 fatty acids such
Page 225 and 226:
old for serious, irreversible or es
Page 227 and 228:
1045 SUBCHRONIC TOXICITY EVALUATION
Page 229 and 230:
sites collected 3 days after inject
Page 231 and 232:
1063 MOLECULAR MECHANISM OF OLANZAP
Page 233 and 234:
esponses, and can be available for
Page 235 and 236:
hence more physiologically relevant
Page 237 and 238:
thesized apoproteins, so we tested
Page 239 and 240:
vate CYP3A5 but could be released b
Page 241 and 242:
1108 STYRENE-INDUCED TOXIC EFFECTS
Page 243 and 244:
1118 THE PRESENCE OF DIETHYL FUMARA
Page 245 and 246:
zebrafish cells were first exposed
Page 247 and 248:
utene-1,4-dial, which has been show
Page 249 and 250:
groups, largely due to lower non-HD
Page 251 and 252:
Exposure to gluten in individuals w
Page 253 and 254:
contrast to VGSC activators such as
Page 255 and 256:
1175 70% HYDROFLUORIC ACID (HF) CUT
Page 257 and 258:
axis. An increase in hyaline drople
Page 259 and 260:
1194 esiRNA AND siRNA HIGH-THROUGHP
Page 261 and 262:
1203 ARYL HYDROCARBON RECEPTOR-DNA
Page 263 and 264:
permeability (calcein), mitochondri
Page 265 and 266:
olytic caspase activation, caspase-
Page 267 and 268:
teristics of a human T-type voltage
Page 269 and 270:
80% of the activity from the yellow
Page 271 and 272:
1251 DEVELOPMENTAL EXPOSURE TO DELT
Page 273 and 274:
1260 MANEB ENHANCES MPP + -INDUCED
Page 275 and 276:
demonstrated by knockdown of beclin
Page 277 and 278:
1278 PINK1 AND MITOCHONDRIAL DYNAMI
Page 279 and 280:
treatment for number of live worms.
Page 281 and 282:
1297 INVESTIGATION OF THE NEUROTOXI
Page 283 and 284:
1306 DEVELOPMENT OF AN IN VITRO ASS
Page 285 and 286:
1315 EVALUATION OF 3- AND 1-METHYLH
Page 287 and 288:
prior to kainic acid-induced seizur
Page 289 and 290:
1334 AFFECT OF GENETIC VARIATION ON
Page 291 and 292:
1346 THE OTHER WORLD OF THE TRANSCR
Page 293 and 294:
strate, leading to excess microvesi
Page 295 and 296:
1368 OVERVIEW OF THERAPEUTIC VACCIN
Page 297 and 298:
to a bovine adrenal cortical epithe
Page 299 and 300:
DOTC had no effects. These results
Page 301 and 302:
1398 PULMONARY TOXICITY OF CERIUM D
Page 303 and 304:
PPARα, LXR, ER, AR and AhR activit
Page 305 and 306:
1417 MECHANISM OF GENDER-DIVERGENT
Page 307 and 308:
els, they disrupt homeostatic contr
Page 309 and 310:
were to characterize exposure of th
Page 311 and 312:
1448 ADVERSE OUTCOME PATHWAYS AND E
Page 313 and 314:
the level in urine was 25% of the m
Page 315 and 316:
1;akt-2 double mutant and pdk-1 mut
Page 317 and 318:
jury effects when compared to contr
Page 319 and 320:
tude than equivalent oral doses. Af
Page 321 and 322:
cells; and increased iNOS and MCP-1
Page 323 and 324:
B6.Cg-Kit W-sh mice. These findings
Page 325 and 326:
1511 STATIN-TREATMENT EFFECTIVELY R
Page 327 and 328:
1520 EFFECT OF INHALATION EXPOSURE
Page 329 and 330:
numbers of IFN-γ producing cells w
Page 331 and 332:
These data indicate that TCDD treat
Page 333 and 334:
esponse to allogenic cells, where P
Page 335 and 336:
larly suppressed LPS-induced TNF-α
Page 337 and 338:
1565 INFLUENCE OF EXPOSURE ROUTE AN
Page 339 and 340:
veloping animals to adverse effects
Page 341 and 342:
the observed CL values were 0.07 L/
Page 343 and 344:
which is most relevant for potentia
Page 345 and 346:
tive impairment, suggesting that ox
Page 347 and 348:
1611 AN IN VITRO METABOLOMICS APPRO
Page 349 and 350:
Expression of the β6 integrin (Itg
Page 351 and 352:
ats (10 μg/kg TCDD). Here we repor
Page 353 and 354:
at liver slices and how the metabon
Page 355 and 356:
with gender differences in AUC and
Page 357 and 358:
oxetine (30 mg/kg reduced to 15 mg/
Page 359 and 360:
eleased from necrotic cells where i
Page 361 and 362:
plants, they are present in surface
Page 363 and 364:
ferentiation (quantitative in-cell
Page 365 and 366:
control for macrophage activation).
Page 367 and 368:
to 0.5μg/ml. Minimal inhibitory co
Page 369 and 370:
lines tested. Given that dex and AT
Page 371 and 372:
tion in the absence of an immune re
Page 373 and 374:
treated rats had lower calcium load
Page 375 and 376:
1740 PROFILING COMPOUNDS WITH CARDI
Page 377 and 378:
dothelial cells confirmed caveolin-
Page 379 and 380:
1758 GINKGO BILOBA EXTRACT INDUCES
Page 381 and 382:
arin-induced suppression of MDR1 ex
Page 383 and 384:
1780 ANTIANDROGENIC AND ANTIPROLIFE
Page 385 and 386:
included in the evaluation, most of
Page 387 and 388:
1799 GUIDANCE ON THE APPLICATION OF
Page 389 and 390:
However, substances with EC3 values
Page 391 and 392:
1816 CD-INDUCED EGFR TRANSACTIVATIO
Page 393 and 394:
1826 KERATIN 7 EXPRESSION IN INDEPE
Page 395 and 396:
centa were collected at the time of
Page 397 and 398:
1845 SYSTEMATIC SCREENING OF YEAST
Page 399 and 400:
underlying the development of co-mo
Page 401 and 402:
eing measured in experimental roden
Page 403 and 404:
ufactured in the US for more than 3
Page 405 and 406:
nine (N7-THB-Gua) and N7-hydroxyphe
Page 407 and 408:
1892 EFFECT OF LAMBDA-CYHALOTHRIN O
Page 409 and 410:
22 in Phase I. Antimicrobial pestic
Page 411 and 412:
kinetic and dynamic differences, an
Page 413 and 414:
iphenyl, saccharin and melamine was
Page 415 and 416:
1930 DEVELOPMENT OF A RELATIVE SOUR
Page 417 and 418:
1939 MODE OF ACTION FOR THE CANCER
Page 419 and 420:
human was about 1.5-fold lower (60
Page 421 and 422:
Disruption of BDEC integrity in alp
Page 423 and 424:
1968 A HUMAN HEPG2 LUCIFERASE ASSAY
Page 425 and 426:
in the offspring during tumor devel
Page 427 and 428:
een developed to investigate perfus
Page 429 and 430:
to 131.73 μg/mL for KLH-specific I
Page 431 and 432:
cell lines (ATCC) were cultured in
Page 433 and 434:
flammation and xenobiotic metabolis
Page 435 and 436:
vide many contributions: with its g
Page 437 and 438:
to-metal joint replacement. For exa
Page 439 and 440:
to be addressed or negotiated. Deci
Page 441 and 442:
especially with anti-TNF therapies.
Page 443 and 444:
genic line Tg(are:eGFP) was created
Page 445 and 446:
2074 COMPUTATIONAL ASSESSMENT OF TH
Page 447 and 448:
2084 INHIBITION OF 11β-HSD1 DECREA
Page 449 and 450:
(T) and express several enzymes inv
Page 451 and 452:
2101 GENISTEIN MODULATION OF BLOOD
Page 453 and 454:
males per group were dosed orally o
Page 455 and 456:
ate the feasibility of assessing re
Page 457 and 458:
changed. Hepatic protein carbonyl l
Page 459 and 460:
sought to examine alterations in he
Page 461 and 462:
2147 A SINGLE AMINO ACID CONTROLS T
Page 463 and 464:
Gstm7) was independent of both CAR
Page 465 and 466:
ility of tungsten trioxide (WO3), t
Page 467 and 468:
ured by real-time PCR array and rel
Page 469 and 470:
glucose, and creatinine levels, and
Page 471 and 472:
Several studies have reported suppr
Page 473 and 474:
exposure between TCDD-exposed labor
Page 475 and 476:
Furthermore, with increasing number
Page 477 and 478:
Society of Toxicology 2010 Author I
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492: Society of Toxicology 2010 Author I
Page 501 and 502: Society of Toxicology 2010 Abstract
Page 513 and 514: 49 th Annual Meeting and ToxExpo A
Page 541: 49 th Annual Meeting and ToxExpo A
Page 547 and 548: The Official Journal of the Society
show all

The Toxicologist - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?